Literature DB >> 17072574

Prospective assessment of fluoroquinolone use in a teaching hospital.

M Méan1, P Pavese, J P Vittoz, L Foroni, C Decouchon, J P Stahl, P François.   

Abstract

The aim of this study was to review the use of fluoroquinolone (FQ) drugs in a teaching hospital and to bring to light the factors associated with FQ misuse. A prospective observational study of FQ prescriptions was conducted in a 2,200-bed teaching hospital. Every hospitalized patient receiving a FQ drug during the 3-week survey period was included. A questionnaire was filled out using medical records and face-to-face interviews with FQ prescribers. An infectious diseases specialist reviewed the questionnaires and analyzed FQ therapy according to local guidelines for FQ prescription. Among the group of 174 patients included, FQ therapy was inappropriate in 88 cases (50.6%; 95% CI 43-58) for the following reasons: inappropriate clinical setting, 43; non-first-line recommendation, 24; inappropriate choice of FQ agent, 9; and inappropriate combination of FQs, 12. FQ prescriptions did not comply with prescription rules in 45 cases (25.9%; 95% CI 20-33). Appropriateness and compliance overlapped for 17 of these 45 patients who received an inappropriate FQ course that did not comply with prescription rules. Finally, FQ therapy was misused for 116 of the 174 patients (66.6%; 95% CI 59-74). Characteristics linked with FQ misuse were hospitalization in surgical wards (p = 0.03), intravenous therapy (p < 0.01), and presumptive therapy (p = 0.05). The FQ misuse rate progressively decreased during the survey period (p = 0.04). FQ misuse was a common phenomenon in the teaching hospital studied. The significant improvement in FQ prescribing practices observed during the study period demonstrates that frequent review of antibiotic use with prescribers is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072574     DOI: 10.1007/s10096-006-0221-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Longitudinal surveillance of antibiotic use in the hospital.

Authors:  D Raveh; Y Levy; Y Schlesinger; A Greenberg; B Rudensky; A M Yinnon
Journal:  QJM       Date:  2001-03

2.  Impact of a hospital-based antimicrobial management program on clinical and economic outcomes.

Authors:  R Gross; A S Morgan; D E Kinky; M Weiner; G A Gibson; N O Fishman
Journal:  Clin Infect Dis       Date:  2001-07-05       Impact factor: 9.079

Review 3.  Appropriate use of antimicrobial agents: challenges and strategies for improvement.

Authors:  Michael S Niederman
Journal:  Crit Care Med       Date:  2003-02       Impact factor: 7.598

4.  Expanding uses of fluoroquinolones: opportunities and challenges.

Authors:  D C Hooper
Journal:  Ann Intern Med       Date:  1998-12-01       Impact factor: 25.391

Review 5.  Comparison of side effects of levofloxacin versus other fluoroquinolones.

Authors:  C Carbon
Journal:  Chemotherapy       Date:  2001       Impact factor: 2.544

6.  Trends in antimicrobial resistance in 1,968 invasive Streptococcus pneumoniae strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates.

Authors:  Jesús Oteo; Edurne Lázaro; Francisco J de Abajo; Fernando Baquero; José Campos
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

7.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

Review 8.  IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: focus on gatifloxacin.

Authors:  Lorenzo Pelly
Journal:  Adv Ther       Date:  2002 Sep-Oct       Impact factor: 3.845

9.  The appropriateness of oral fluoroquinolone-prescribing in the long-term care setting.

Authors:  T D Pickering; J H Gurwitz; D Zaleznik; J P Noonan; J Avorn
Journal:  J Am Geriatr Soc       Date:  1994-01       Impact factor: 5.562

10.  Generalized additive model demonstrates fluoroquinolone use/resistance relationships for Staphylococcus aureus.

Authors:  Pierre Berger; Laurence Pascal; Catherine Sartor; Jean Delorme; Philippe Monge; Christine Penot Ragon; Martine Charbit; Roland Sambuc; Michel Drancourt
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

View more
  6 in total

1.  Drug use evaluation of moxifloxacin (avelox) using a hand-held electronic device at a canadian teaching hospital.

Authors:  Jennifer A E Samilski; Tim T Y Lau; Dean H T Elbe; Amneet K Aulakh; Eric M C Lun
Journal:  P T       Date:  2012-05

2.  Evaluation of an intervention to improve blood culture practices: a cluster randomised trial.

Authors:  P Pavese; M Maillet; V Vitrat-Hincky; C Recule; J-P Vittoz; A Guyomard; A Seigneurin; P François
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-02       Impact factor: 3.267

3.  Assessment of linezolid prescriptions in three French hospitals.

Authors:  C Dentan; E Forestier; M Roustit; S Boisset; S Chanoine; O Epaulard; P Pavese
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-26       Impact factor: 3.267

Review 4.  Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.

Authors:  Tomasz Kloskowski; Sylwia Frąckowiak; Jan Adamowicz; Kamil Szeliski; Marta Rasmus; Tomasz Drewa; Marta Pokrywczyńska
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

5.  Unnecessary use of fluoroquinolone antibiotics in hospitalized patients.

Authors:  Nicole L Werner; Michelle T Hecker; Ajay K Sethi; Curtis J Donskey
Journal:  BMC Infect Dis       Date:  2011-07-05       Impact factor: 3.090

6.  Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016.

Authors:  Ibrahim A Oreagba; Kazeem A Oshikoya; Comfort Ogar; Abiodun O Adefurin; Ali Ibrahim; Olufunsho Awodele; Yetunde Oni
Journal:  Pharmacol Res Perspect       Date:  2017-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.